Processa Pharmaceuticals, Inc. Increase Decrease In Operating Lease Liability
Processa Pharmaceuticals, Inc. (PCSA) reported Increase Decrease In Operating Lease Liability of -$66.91 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$21.83K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$22.76K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$22.31K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2025 was -$66.91K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2024 was -$83.65K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2023 was -$78.90K.
- Processa Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2022 was -$87.94K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$21.83K derived: sum of 2 quarters · filed 2026-03-18 | -$44.59K derived: sum of 3 quarters · filed 2026-08-14 | -$66.91K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$21.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$44.59K derived: sum of 2 quarters · filed 2026-08-14 | -$66.91K 10-Q · filed 2025-11-06 | -$88.78K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$22.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$45.07K 10-Q · filed 2026-08-14 | -$66.95K derived: sum of 3 quarters · filed 2026-08-14 | -$87.49K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$22.31K 10-Q · filed 2026-05-07 | -$44.19K derived: sum of 2 quarters · filed 2026-05-07 | -$64.73K derived: sum of 3 quarters · filed 2026-05-07 | -$84.88K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$21.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$42.42K derived: sum of 2 quarters · filed 2026-03-18 | -$62.57K derived: sum of 3 quarters · filed 2026-03-18 | -$83.65K 10-K · filed 2026-03-18 |
| 2024-09-30 | -$20.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$40.69K derived: sum of 2 quarters · filed 2025-11-06 | -$61.78K 10-Q · filed 2025-11-06 | -$82.74K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$20.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$41.23K 10-Q · filed 2025-08-07 | -$62.20K derived: sum of 3 quarters · filed 2025-08-07 | -$81.89K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$21.08K 10-Q · filed 2025-05-08 | -$42.05K derived: sum of 2 quarters · filed 2025-05-08 | -$61.75K derived: sum of 3 quarters · filed 2025-05-08 | -$81.05K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$20.97K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$40.66K derived: sum of 2 quarters · filed 2025-03-20 | -$59.97K derived: sum of 3 quarters · filed 2025-03-20 | -$78.90K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$19.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$39.00K derived: sum of 2 quarters · filed 2024-10-30 | -$57.93K 10-Q · filed 2024-10-30 | -$76.45K derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | -$19.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$38.23K 10-Q · filed 2024-08-13 | -$56.75K derived: sum of 3 quarters · filed 2024-08-13 | -$78.91K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$18.93K 10-Q · filed 2024-05-10 | -$37.44K derived: sum of 2 quarters · filed 2024-05-10 | -$59.61K derived: sum of 3 quarters · filed 2024-05-10 | -$83.67K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$18.52K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$40.68K derived: sum of 2 quarters · filed 2024-03-29 | -$64.74K derived: sum of 3 quarters · filed 2024-03-29 | -$87.94K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$22.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$46.23K derived: sum of 2 quarters · filed 2023-11-13 | -$69.42K 10-Q · filed 2023-11-13 | -$92.50K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$24.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$47.26K 10-Q · filed 2023-08-10 | -$70.33K derived: sum of 3 quarters · filed 2023-08-10 | -$92.14K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$23.20K 10-Q · filed 2023-05-15 | -$46.27K derived: sum of 2 quarters · filed 2023-05-15 | -$68.08K derived: sum of 3 quarters · filed 2023-05-15 | -$89.45K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$23.08K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$44.88K derived: sum of 2 quarters · filed 2023-03-30 | -$66.25K derived: sum of 3 quarters · filed 2023-03-30 | -$87.20K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$21.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$43.17K derived: sum of 2 quarters · filed 2022-11-08 | -$64.12K 10-Q · filed 2022-11-08 | -$82.73K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$21.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$42.32K 10-Q · filed 2022-08-11 | -$60.93K derived: sum of 3 quarters · filed 2022-08-11 | -$80.99K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$20.95K 10-Q · filed 2022-05-12 | -$39.56K derived: sum of 2 quarters · filed 2022-05-12 | -$59.62K derived: sum of 3 quarters · filed 2022-05-12 | -$79.22K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$18.61K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$38.67K derived: sum of 2 quarters · filed 2022-03-30 | -$58.27K derived: sum of 3 quarters · filed 2022-03-30 | -$77.49K 10-K · filed 2022-03-30 |
| 2020-09-30 | -$20.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$39.66K derived: sum of 2 quarters · filed 2021-11-12 | -$58.88K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$19.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$38.82K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$19.22K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |